A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease.

Carpenter PA, Lowder J, Johnston L, Frangoul H, Khoury H, Parker P, Jerome KR, McCune JS, Storer B, Martin P, Appelbaum F, Abonour R, Westervelt P, Anasetti C
Biol Blood Marrow Transplant. 2005 11 (6): 465-71

PMID: 15931635 · DOI:10.1016/j.bbmt.2005.03.002

MeSH Terms (17)

Acute Disease Adolescent Adult Aged Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Child Child, Preschool Female Graft vs Host Disease Hematologic Neoplasms Hematopoietic Stem Cell Transplantation Humans Male Middle Aged Steroids Survival Analysis

Connections (1)

This publication is referenced by other Labnodes entities: